Satori Pharmaceuticals, a Cambridge, MA-based developer of treatments for Alzheimer’s disease, has raised $7 million in equity funding, according to an SEC filing. The funding is part of Satori’s previously disclosed $22 million round of financing, according to an e-mail from company director Daphne Zohar, a managing partner at PureTech Ventures in Boston. Satori’s investors include PureTech, InterWest Partners, New Enterprise Associates, Prospect Venture Partners, and others. Zohar, whose firm formed Satori in 2005, was also the startup’s founding CEO, according to Satori’s website.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
